ReviewFrontiers in cell and developmental biology2026
Decoding signaling crosstalk in pulpitis: pathogenesis and precision therapeutics.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irreversible pulpitis presents a complex pathological challenge, marked by severe inflammation within the low-compliance dentin chamber. Its progression to pulpal necrosis is governed by intricate molecular interactions. Hyperactivation of the TLR/NF-κB and MAPK pathways triggers a pro-inflammatory cascade, while HIF-1α accumulation under hypoxic conditions induces significant metabolic reprogramming. Meanwhile, the NLRP3 inflammasome exacerbates tissue damage by promoting programmed cell death. Endogenous Wnt/β-catenin and TGF-β/Smad signaling pathways strive to promote structural repair and dentinogenesis, but are often suppressed by the hyperactive inflammatory environment. Recent translational research highlights the potential of targeted molecular interventions to address this pathological imbalance. This review synthesizes emerging therapeutic strategies aimed at these key pathways, emphasizing the pharmacological use of specific phytochemicals, epigenetic regulators, and specialized pro-resolving mediators, particularly Resolvin E1, which collaboratively attenuate NF-κB-driven inflammation while enhancing Wnt- and TGF-β-mediated regenerative processes. Additionally, this review discusses the development of next-generation, microenvironment-responsive biomaterials designed to adapt dynamically to pulpal hypoxia and oxidative stress. Ultimately, understanding these signaling interactions lays a molecular foundation for advancing objective, biomarker-based diagnostics and precision therapeutics, offering promising prospects for predictable vital pulp therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.